Docetaxel

New Zealand - English - Medsafe (Medicines Safety Authority)

Buy It Now

Active ingredient:
Docetaxel trihydrate 25.177 mg equivalent to anhydrous docetaxel 20mg
Available from:
REX Medical Ltd
INN (International Name):
Docetaxel trihydrate 25.177 mg (equivalent to anhydrous docetaxel 20mg)
Dosage:
20 mg/mL
Pharmaceutical form:
Concentrate for infusion
Composition:
Active: Docetaxel trihydrate 25.177 mg equivalent to anhydrous docetaxel 20mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection
Units in package:
Vial, glass, Diluent, 1.5 mL
Class:
Prescription
Prescription type:
Prescription
Manufactured by:
Cipla Ltd
Therapeutic indications:
Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.
Product summary:
Package - Contents - Shelf Life: Vial, glass, Diluent - 1.5 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 20 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)
Authorization number:
TT50-7708
Authorization date:
2006-06-23

Similar products

Search alerts related to this product

Share this information